A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07221357
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Untreated, Unresectable, or Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pumitamig — DRUG
    Specified dose on specified days
  • FOLFOX — DRUG
    Specified dose on specified days
  • FOLFIRI — DRUG
    Specified dose on specified days
  • Bevacizumab — DRUG
    Specified dose on specified days
  • CAPOX — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Key Dates

Start date
Dec 31, 2025
Status verified
May 2026
Primary completion
Feb 2, 2030
Completion
Mar 11, 2034

Study Design

Enrollment
990 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A1
  • Experimental: Arm A2
  • Other: Arm B
  • Experimental: Arm C
  • Other: Arm D

Primary Outcome Measure

Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment [ Time Frame: Up to 5 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (49)

FacilityCityStateZIPSite coordinators
Local Institution - 0428TucsonArizona85724
Site 0428
Local Institution - 0432SpringdaleArkansas72762
Site 0432
Local Institution - 0447La JollaCalifornia92037
Site 0447
USC/Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Sandra Algaze, Site 0263
818-406-8072
University of California, Irvine (UCI) Health - UC Irvine Medical CenterOrangeCalifornia92868
Farshid Dayyani, Site 0345
714-456-5153
Local Institution - 0317San FranciscoCalifornia94115
Site 0317
Local Institution - 0330Santa MonicaCalifornia90404
Site 0330
Local Institution - 0293StanfordCalifornia94305
Site 0293
Florida Cancer Specialists - EastCape CoralFlorida33990
Todd Gersten, Site 0574
561-366-4100
Florida Cancer Specialists - NorthSt. PetersburgFlorida33705
Maen Hussein, Site 0575
727-216-1143
Moffitt Cancer CenterTampaFlorida33612
Tiago Biachi de Castria, Site 0269
646-673-0129
Local Institution - 0276AtlantaGeorgia30342
Site 0276
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMariettaGeorgia30060
Walid Shaib, Site 0369
770-281-5124
Local Institution - 0030ChicagoIllinois60611
Site 0030
Local Institution - 0433ChicagoIllinois60637
Site 0433
Local Institution - 0638Fort WayneIndiana46805
Site 0638
Local Institution - 0335Iowa CityIowa52242
Site 0335
Local Institution - 0262BaltimoreMaryland21287
Site 0262
Maryland Oncology Hematology - Silver SpringSilver SpringMaryland20904
Danubia Hester, Site 0580
Local Institution - 0471BostonMassachusetts02114-
Local Institution - 0430Ann ArborMichigan48109
Site 0430
Local Institution - 0254Grand RapidsMichigan49546
Site 0254
Minnesota OncologyMaple GroveMinnesota55369
Robert Delaune, Site 0572
Local Institution - 0318Kansas CityMissouri64111
Site 0318
Washington University School OF Medicine-Siteman Cancer CenterSt LouisMissouri63110
Moh'd Khushman, Site 0336
314-273-3564
University Of Nebraska Medical CenterOmahaNebraska68198
Laura Tenner, Site 0334
402-559-5600
Northwell Health/ RJ Zuckerberg Cancer CenterLake SuccessNew York11042
Nicholas Hornstein, Site 0429
323-533-7275
Local Institution - 0270MineolaNew York11501
Site 0270
Local Institution - 0273New Hyde ParkNew York11042
Site 0273
Local Institution - 0290CharlotteNorth Carolina28207
Site 0290
Sanford Fargo Medical CenterFargoNorth Dakota58102
Jeffrey Wiisanen, Site 0526
701-234-2358
Local Institution - 0339ColumbusOhio43210
Site 0339
Local Institution - 0605Oklahoma CityOklahoma73104
Site 0605
Lehigh Valley Health NetworkAllentownPennsylvania18103
Maged Khalil, Site 0348
Local Institution - 0604PittsburghPennsylvania15232
Site 0604
Sanford Cancer CenterSioux FallsSouth Dakota57104
Jonathan Bleeker, Site 0312
605-328-8000
Local Institution - 0333NashvilleTennessee37203
Site 0333
SCRI Oncology PartnersNashvilleTennessee37203
Meredith Pelster, Site 0570
615-986-4366
Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center NorthArlingtonTexas76012
Laith Abushahin, Site 0573
Texas Oncology, PAAustinTexas78705
Vivian Cline, Site 0571
512-427-9400
Local Institution - 0252HoustonTexas77030
Site 0252
Texas Oncology - San AntonioSan AntonioTexas78240
Sridhar Beeram, Site 0576
210-615-1988
Local Institution - 0426Salt Lake CityUtah84102
Site 0426
Local Institution - 0278FairfaxVirginia22031
Site 0278
Virginia Oncology AssociatesNorfolkVirginia23502
YUE ZHANG, Site 0577
757-466-8683
Local Institution - 0491EdmondsWashington98026-8032
Site 0491
Local Institution - 0253SeattleWashington98109
Site 0253
Local Institution - 0629SpokaneWashington99218
Site 0629
Northwest Cancer Specialists, P.C.VancouverWashington98684
Spencer Shao, Site 0578
503-528-5005

Find similar trials in Tucson, AZ

By research site
Local Institution - 0428· Tucson, AZLocal Institution - 0432· Springdale, ARLocal Institution - 0447· La Jolla, CAUSC/Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of California, Irvine (UCI) Health - UC Irvine Medical Center· Orange, CALocal Institution - 0317· San Francisco, CA